Results 71 to 80 of about 54,104 (311)
International Journal of Infectious Diseases, 2021 Objectives: The aim was to evaluate the safety and effectiveness of thalidomide, an immunomodulatory agent, in combination with glucocorticoid, for the treatment of COVID-19 patients with life-threatening symptoms.
Yuping Li +12 more
doaj +1 more source
BMJ, 1994 EDITOR, - Use of thalidomide only on a named patient basis does not necessarily mean that patients are protected from its side effects, as implied by Baroness Cumberlege, the junior health minister.1 According to Sir William Asscher, the former chairman of the Committee on the Safety of Medicines, “the companies who supply a drug for named patient use ...
openaire +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden +3 more
wiley +1 more source
Thalidomide in treatment of connective diseases and vasculities
Reumatismo, 2011 Thalidomide is an immunomodulatory, anti-inflammatory and anti-angiogenic drug. Thalidomide exerts its effects by decreasing circulating CD4 positive T-cells and stimulating CD8 positive T-cells, by increasing the number of Natural Killer cells and T ...
D. Ribatti, F.P. Cantatore, N. Maruotti
doaj +1 more source
Development and application of novel analytical methods for molecularly targeted cancer therapeutics [PDF]
, 2011 A detailed understanding of correlations of drug levels with drug action is an important aspect of the pre-clinical, clinical development and routine use of anti-cancer drugs. In furtherance of this important aim, the research in this thesis sought to
Roche, Sandra
core
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim Although regulatory responses to safety signals have been studied, pregnancy‐specific data and their dissemination to medical professionals remain unclear. This study examined the characteristics and temporal trends of teratological safety signals prompting the European Medicines Agency to implement risk minimization measures.
Yrea R. J. van Rijt‐Weetink +9 more
wiley +1 more source
Novel thalidomide analogues, “me too†drugs and the Brazilian law
Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia, 2013 In Brazil, thalidomide has been used virtually without interruption since it was launched as a new and revolutionary sedative drug in 1956. After 1965, when its efficacy to treat erythema nodosum leprosum (ENL) was discovered, it was regarded as an ...
Francisco José Roma Paumgartten
doaj +2 more sources
Arterial thrombosis and thalidomide
, 2008 Arterial emboli are largely a reflection of cardiac disease. Thalidomide is an antiangiogenic drug used in cancer therapy. Venous thrombosis incidence increased during treatment with thalidomide. We reported arterial thrombosis in two cases with multiple
Eren, M. Nesimi +2 more
core +1 more source
Drug‐coated balloons: From conventional designs to next‐generation innovations in vascular therapy
BMEMat, EarlyView.This review traces the evolution of drug‐coated balloons (DCBs) from conventional designs to next‐generation platforms. We highlight innovations in balloon engineering, coating technologies, and therapeutic agents that enhance localized drug delivery while addressing challenges in efficiency, safety, and biocompatibility for vascular and emerging non ...
Lu Zhang +5 more
wiley +1 more source
Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease. [PDF]
PLoS ONE, 2013 Thalidomide is a tumor necrosis factor alpha (TNFα) inhibitor which has been found to have abilities against tumor growth, angiogenesis and inflammation.
Ping He +4 more
doaj +1 more source